List of publications

 

BETPSY Project

 

Biomarkers in autoimmune EncephaliTis and

Paraneoplastic neurological SYndromes

 

 

Scientific articles 

Farina et al. Mononeuritis multiplex following immune checkpoint inhibitors in malignant pleural mesothelioma. Frontiers. 2024.  https://doi.org/10.3389/fneur.2024.1338899 (WP2)

 

Villagran-Garcia et al. Revisiting anti-Hu paraneoplastic autoimmunity: phenotypic characterization and cancer diagnosis. Brain Commun. 2023. 10.1093/braincomms/fcad247 (WP2)

 

Farina A. et al. Neurological outcomes in immune checkpoint inhibitor-related neurotoxicity, Brain Commun, Volume 5, Issue 3, 2023, fcad169, https://doi.org/10.1093/braincomms/fcad169 (WP2)

 

Bartley C. et al. Detection of High-Risk Paraneoplastic Antibodies against TRIM9 and TRIM67 Proteins. Ann Neurol. 2023. doi: 10.1002/ana.26776 (WP2)

 

Theuriet J. et al. Peripheral nervous system involvement accompanies central nervous system involvement in anti-glial fibrillary acidic protein (GFAP) antibody-related disease. J Neurol. 2023 ;270(11):5545-5560. doi: 10.1007/s00415-023-11908-7 (WP2)

 

Vogrig et al. Different Genetic Signatures of Small-Cell Lung Cancer Characterize Anti-GABABR and Anti-Hu Paraneoplastic Neurological Syndromese. Ann Neurol. 2023. https://doi.org/10.1002/ana.26784. (WP4)

 

Cluse F et al. Trigeminal Nerve Involvement in Bulbar-Onset Anti-IgLON5 Disease. Neurol Neuroimmunol Neuroinflamm. 2023 . doi: 10.1212/NXI.0000000000200153. (WP2)

 

Alentorn A et al. Spatial and Ecological Factors Modulate the Incidence of Anti-NMDAR Encephalitis—A Systematic Review. Neurol Neuroimmunol Biomedecine. 2023.  https://doi.org/10.3390/biomedicines11061525. (WP2)

 

Schiff P et al. Anti-LGI1 Encephalitis With Co-occurring IgLON5 Antibodies: Clinical Features and Human Leukocyte Antigen Haplotypes. Neurol Neuroimmunol Neuroinflamm. 2023. doi: 10.1212/NXI.0000000000200126. (WP2)

 

Ciano-Petersen NL et al. Prognostic Value of Persistent CSF Antibodies at 12 Months in Anti-NMDAR Encephalitis. Neurol Neuroimmunol Neuroinflamm. 2023. doi: 10.1212/NXI.0000000000200108.  (WP2)

 

Vilaseca, A. et al. The expanding spectrum of antibody-associated cerebellar ataxia: report of two new cases of anti-AP3B2 ataxia. J Neurol. 2023. https://doi.org/10.1007/s00415-023-11732-z (WP2)

 

Flet-Berliac., et al. Long-term outcome of paediatric anti-N-methyl-D-aspartate receptor encephalitis. Develomental medicine & child neurology 2023.  https://doi.org/10.1111/dmcn.15429 (WP2)

 

Faure F., et al. A Pilot Study to Develop Paraneoplastic Cerebellar Degeneration Mouse Model. The Cerebellum 2023. https://doi.org/10.1007/s12311-023-01524-6 (WP2)

 

Khatib L., et al. Autoimmune Cerebellar Ataxia Associated withAnti‑Glutamate Receptor δ2 Antibodies: a Rare but Treatable Entity. The Cerebellum. 2023. https://doi.org/10.1007/s12311-023-01523-7 (WP2)

 

Farina A., et al. Anti-Hu Antibodies in Patients With Neurologic Side Effects of Immune Checkpoint Inhibitors. Neurol Neuroimmunol Neuroinflamm. 2023DOI: https://doi.org/10.1212/NXI.0000000000200058 (WP2)

 

Vabanesi M., et al. SOX1 antibody-related paraneoplastic neurological syndromes: clinical correlates and assessment of laboratory diagnostic techniques. Journal of neurology. 202310.1007/s00415-022-11523-y (WP2)

 

Benoit J, et al. Early-Stage Contactin-Associated Protein-like 2 Limbic Encephalitis Clues for Diagnosis. Neurol Neuroimmunol Neuroinflamm. 2022https://doi.org/10.1212/NXI.0000000000200041 (WP2)

 

Moritz C, et al. Conformation-stabilizing ELISA and cell-based assays reveal patient subgroups targeting three different epitopes of AGO1 antibodies. Front. Immunol. 2022https://doi.org/10.3389/fimmu.2022.972161 (WP2)

 

Flet-Berliac L, et al. Long-term outcome of paediatric anti-N-methyl-D-aspartate receptor encephalitis. Dev Med Child Neurol. 2022https://doi.org/10.1111/dmcn.15429 (WP2)

 

Villagran-Garcia M et al. Paraneoplastic neurological syndromes associated with renal or bladder cancer: case series and PRISMA-IPD systematic review. J Neurol. 2022. doi: 10.1007/s00415-022-11356-9 (WP2)

 

Peter E, Do LD, et al. Cerebellar Ataxia With Anti-DNER Antibodies: Outcomes and Immunologic Features. Neurol Neuroimmunol Neuroinflamm. 2022doi: 10.1212/NXI.0000000000200018 (WP2)

 

Peter E, Treilleux I, et al. Immune and Genetic Signatures of Breast Carcinomas Triggering Anti-Yo-Associated Paraneoplastic Cerebellar Degeneration. Neurol Neuroimmunol Neuroinflamm. 2022. 10.1212/NXI.0000000000200015 (WP4)

 

Peris Sempre V, Muñiz-Castrillo S, et al. Human Leukocyte Antigen Association Study Reveals DRB1*04:02 Effects Additional to DRB1*07:01 in Anti-LGI1 Encephalitis. Neurol Neuroimmunol Neuroinflamm. 2022. DOI: https://doi.org/10.1212/NXI.0000000000001140 (WP3)

Lardeux P, and al. Core cerebrospinal fuid biomarker profile in anti‑LGI1 encephalitisJournal of neurology. 2022. https://doi.org/10.1007/s00415-021-10642-2 (WP2)

Tholance Y, Antoine JC, et al. Anti-FGFR3 antibody epitopes are functional sites and correlate with the neuropathy patternJournal of neuroimmunology. 2021. https://doi.org/10.1007/s00415-021-10870-6 (WP2)

Vogrig A, Péricart S, et al. Immunopathogenesis and proposed clinical score for identifying Kelch-like protein-11 encephalitisBrain Communications. 2021. https://doi.org/10.1093/braincomms/fcab185 (WP2)

Do L, Moritz C, et al. Argonaute Autoantibodies as Biomarkers in Autoimmune Neurologic DiseasesNeurol Neuroimmunol Neuroinflamm. 2021. DOI: https://doi.org/10.1212/NXI.0000000000001032 (WP2)

Muñiz-Castrillo S, Hedou J, et al. Distinctive clinical presentation and pathogenic specificities of anti-AK5 encephalitis. Brain, 2021; awab153, https://doi.org/10.1093/brain/awab153 (WP3)

Muñiz‑Castrillo S, Haesebaert J et al. Clinical and Prognostic Value of Immunogenetic Characteristics in Anti-LGI1 Encephalitis. Neurol Neuroimmunol Neuroinflamm. 2021. DOI: https://doi.org/10.1212/NXI.0000000000000974 (WP3)

Muñiz‑Castrillo S, Vogrig A et al. Familial autoimmunity in neurological patients with GAD65 antibodies: an interview-based study. Journal of neurology. 2021. https://doi.org/10.1007/s00415-021-10424-w (WP3)

Moritz C, et al. CIDP Antibodies Target Junction Proteins and Identify Patient Subgroups. Neurol Neuroimmunol Neuroinflamm. 2021. doi.org/10.1212/NXI.0000000000000944 (WP2)

Vogrig A, et al. Cranial Nerve Disorders Associated with Immune Checkpoint Inhibitors. Neurology. 2020. doi.org/10.1212/WNL.0000000000011340 (WP2)

Moritz C et al. Proper definition of the set of autoantibody-targeted antigens relies on appropriate reference group selection. New biotechnology. 2020. doi.org/10.1016/j.nbt.2020.08.007 (WP2)

Hébert J, Riche B et al. Epidemiology of paraneoplastic neurologic syndromes and autoimmune encephalitides in France. Neurol Neuroimmunol Neuroinflamm. 2020; 7 (6). https://doi.org/10.1212/NXI.0000000000000883 (WP1-WP6)

Muñiz‑Castrillo S, Joubert B, et al. Anti-CASPR2 clinical phenotypes correlate with HLA et immunological features. J Neurol Neurosurg Psychiatry. 2020; 0:1–9. doi.org/10.1136/jnnp-2020-323226 (WP3)

 

Muñiz‑Castrillo S, Vogrig A, Joubert B, et al. Transient Neurological Symptoms Preceding Cerebellar Ataxia with Glutamic Acid Decarboxylase Antibodies. Cerebellum. 2020; 19 715-721. https://doi.org/10.1007/s12311-020-01159-x (WP2)

 

Vogrig A, Muñiz‑Castrillo S, Joubert B, et al. Central nervous system complications associated with immune checkpoint inhibitors. J Neurol Neurosurg Psychiatry. 2020; . doi: 10.1136/jnnp-2020-323212 (WP2)

 

Simard C, Vogrig A, Joubert B, et al. Clinical spectrum and diagnostic pitfalls of neurologic syndromes with Ri antibodies. Neurol Neuroimmunol Neuroinflamm. 2020; 7:e699. DOI: https://doi.org/10.1212/NXI.0000000000000699 (WP2)

 

Déchelotte B, Muñiz‑Castrillo S, Joubert B, et al. Diagnostic yield of commercial immunodots to diagnose paraneoplastic neurological syndromes. Neurol Neuroimmunol Neuroinflamm. 2020; 7(3):e701. https://doi.org/10.1212/NXI.0000000000000701 (WP2)

 

Muñiz‑Castrillo S, Ambati A, Dubois V, et al. Primary DQ effect in the association between HLA and neurological syndromes with anti-GAD65 antibodies. J Neurol. 2020; 267:1906-1911. http://dx.doi.org/10.1007/s00415-020-09782-8 (WP3)

 

Vogrig. A, Gigli, G.L., Segatti, S. et al. Epidemiology of paraneoplastic neurological syndromes: a population-based study. J Neurol. 2020; 267: 26-35http://dx.doi.org/10.1007/s00415-019-09544-1 (WP2)

 

Joubert, B., Belbezier, A., Haesebaert, J. et al. Long-term outcomes in temporal lobe epilepsy with glutamate decarboxylase antibodies. J Neurology. 2020. https://doi.org/10.1007/s00415-020-09807-2 (WP2)

 

 

Reviews

Farina A et al. Neurological adverse events of immune checkpoint inhibitors and the development of paraneoplastic neurological syndromes. Lancet Neurol. 2024; 23: 81–94doi.10.1016/S1474-4422(23)00369-1.(WP2)

 

Vogrig et al. Sudden unexpected death in epilepsy and ictal asystole in patients with autoimmune encephalitis: a systematic review. Neurological Sciences. 2024. https://doi.org/10.1007/s10072-023-07280-z (WP2) 

 

Villagrán-García M et al. Autonomic nervous system involvement in autoimmune encephalitis and paraneoplastic neurological syndromes. Rev Neurol. 2023. doi: 10.1016/j.neurol.2023.12.001 (WP2)

 

Farina A et al. Neurological adverse events of immune checkpoint inhibitors: An update of clinical presentations, diagnosis, and management. Revue neurologique. 2023. https://doi.org/10.1016/j.neurol.2023.03.003 (WP2)

 

Campérat L et al. Autoimmune neuromyotonia. Curr Opin Neurol. 2022. 10.1097/WCO.0000000000001104. (WP2)

 

Antoine JC. Sensory neuronopathies, diagnostic criteria and causes. Curr Opin Neurol. 2022. Volume 4, Issue 4, 2022, fcac196, 10.1097/WCO.0000000000001105. (WP2)

 

Ciano-Petersen NL et al. Cytokine dynamics and targeted immunotherapies in autoimmune encephalitis. Brain communications. 2022. Volume 4, Issue 4, 2022, fcac196, https://doi.org/10.1093/braincomms/fcac196 (WP2)

 

Vaišvilas M, Ciano-Petersen NL, et al. Paraneoplastic encephalitis: clinically based approach on diagnosis and management. Postgrad Med J. 2022 -141766doi: 10.1136/postgradmedj-2022-141766 (WP2)

 

Muñiz‑Castrillo S, Vogrig A, et al. Novelties in Autoimmune and Paraneoplastic Cerebellar Ataxias: Twenty Years of ProgressesThe Cerebellum. 2022.https://doi.org/10.1007/s12311-021-01363-3 (WP2)


Ciano-Petersen N, Muñiz‑Castrillo S, et al. Immunomodulation in the acute phase of autoimmune encephalitisRevue neurologique. 2022. https://doi.org/10.1016/j.neurol.2021.12.001 (WP2)

 

Ciano-Petersen N et al. Current Status of Biomarkers in Anti-N-Methyl-D-Aspartate Receptor Encephalitis. Int J Mol Sci. 2021. doi: 10.3390/ijms222313127 (WP2)


Binks S, Uy C, Honnorat J, Irani S. Paraneoplastic neurological syndromes: a practical approach to diagnosis and management. Pract Neurol. 2021http://dx.doi.org/10.1136/practneurol-2021-003073 (WP2)

 

Graus F, Vogrig A, Muñiz-Castrillo S, et al. Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes. Neurol Neuroimmunol Neuroinflamm. 2021. DOI: 10.1212/NXI.0000000000001014 (WP2)

 

Vogrig A, Muñiz-Castrillo S, et al. How to diagnose and manage neurological toxicities of immune checkpoint inhibitors: an updateJournal of neurology. 2021. https://doi.org/10.1007/s00415-021-10870-6 (WP2)

 

Fels E, Muñiz‑Castrillo S, et al. Role of LGI1 protein in synaptic transmission: From physiology to pathologyNeurobiology of disease. 2021. doi: 10.1016/j.nbd.2021.105537 (WP2)

 

Wiendl H, Gross C, et al. Fundamental mechanistic insights from rare but paradigmatic neuroimmunological diseasesA Systematic Review. Nature Reviews Neurology 2021. https://doi.org/10.1038/s41582-021-00496-7 (WP5)

 

Marini A, Bernardini A, et al. Neurologic Adverse Events of Immune Checkpoint Inhibitors: A Systematic ReviewNeurology 2021. DOI: https://doi.org/10.1212/WNL.0000000000011795 (WP2)

 

Mitoma H, Honnorat J et al. Fundamental Mechanisms of Autoantibody-Induced Impairments on Ion Channels and Synapses in Immune-Mediated Cerebellar Ataxias. Int. J. Mol. Sci. 2020, 21, 4936https://doi:10.3390/ijms21144936 (WP2)

 

Muñiz-Castrillo S, et al. Diagnostic des encéphalites auto-immunes. Pratique Neurologique – FMC 2020. doi.org/10.1016/j.praneu.2020.08.006 (WP2) 

 

Vogrig A, Muñiz‑Castrillo S, Desestret V. Pathophysiology of paraneoplastic and autoimmune encephalitis: genes, infections, and checkpoint inhibitors. Ther Adv Neurol Disord. 2020; 13:1-15https://doi.org/10.1177/1756286420932797 (WP2)

  

Yshii L, Bost C, Liblau R. Immunological Bases of Paraneoplastic Cerebellar Degeneration and Therapeutic Implications. Frontiers in immunology. 2020; 11:911 https://doi.org/10.3389/fimmu.2020.00991 (WP5)

 

Muñiz‑Castrillo S, Vogrig A, Honnorat J. Associations between HLA and autoimmune neurological diseases with autoantibodies. Autoimmun Highlights. 2020; 11:2. https://doi.org/10.1186/s13317-019-0124-6 (WP3)

 

 

Letters

Mongay-Ochoa N, Vogrig A, Muñiz‑Castrillo S, Honnorat J. Anti‑Hu‑associated paraneoplastic syndromes triggered by immune‑checkpoint inhibitor treatment. J Neurol. 2020https://doi.org/10.1007/s00415-020-09940-y (WP2)

 

Vogrig A, Muñiz‑Castrillo S, Honnorat J. Value of onconeural antibodies in checkpoint inhibitor-related toxicities. Ann Neurol. 2020. https://doi.org/10.1002/ana.25764 (WP2)

 

 

Others

Quero K, Joubert B, et al. Paraneoplastic cerebellar degeneration associated with Hodgkin Lymphoma: A french retrospective cohort. Abstract EP1140. 25th congress of European Hematology Association (EHA). 2020